Cipla

Leading Practices

• Cipla has an active Index Country expansion strategy for the range of its Index Disease products.
• Cipla shows strong performance in building local manufacturing capabilities highlighted by its partnership with the government of Uganda for production of ARVs and malaria (since December 2008).
• The company is one of the partners of DNDi for production and distribution of fixed-dose, artesunate-based Combination Therapies for malaria for endemic countries.

Changes Compared to Index 2008

• A manufacturing partnership with the government of Uganda for ARVs was established in 2008 (Please refer to the related leading practice).
• Cipla is one of the generics companies involved in the HIV/AIDS equitable pricing scheme of the Clinton Health Access Initiative.

Suggested Areas for Improvement

• Cipla does not have formal ATM representation at a senior management level.
• The company is not transparent in areas such as public policy positions, lobbying activities, marketing in the Index Countries, research pipeline and research investments.
• The company does not carry out public annual reporting on ATM-related policies, performance and objectives.